134069-68-4 TDN345

中文名称: TDN345
英文名称: 8-[4,4-bis(4-fluorophenyl)butyl]-3-tert-butyl-4-methylidene-1-oxa-3,8-diazaspiro[4.5]decan-2-one
CAS号
分子式: C₂₈H₃₄F₂N₂O₂
分子量: 468.58
更新日期: 2026-06-23

名称和标识

中文名: TDN345
英文名: 8-[4,4-bis(4-fluorophenyl)butyl]-3-tert-butyl-4-methylidene-1-oxa-3,8-diazaspiro[4.5]decan-2-one
CAS号: 134069-68-4
分子式: C28H34F2N2O2
分子量: 468.58
中文别名: 化合物 T13107; 化合物 TDN345
英文别名: TDN 345; TDN-345; 1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-; 1-Oxa-3,8-diazaspiro(4.5)decan-2-one,8-(4,4-bis(4-fluorophenyl)butyl)-3-(1,1-dimethylethyl)-4-methylene; 8-[4,4-bis(4-fluorophenyl)butyl]-2-tert-butyl-1-methylidene-4-oxa-2,8-diazaspiro[4.5]decan-3-one

用途与制备

生物活性 TDN345 A 是一种 Ca2+ 拮抗剂，主要用于血管和老年痴呆疾病，例如阿尔茨海默症的研究。
体外研究 TDN-345 (10 μM) significantly increases the intracellular NGF content in the time-course study. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM. The ED 50 is 0.88 μM.
体内研究 TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP.

医药

词条详情加载中…